1.Moya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. World J Orthop. 2015;6(8):590–601.
2.Herndon JH, Aufranc OE. Avascular necrosis of the femoral head in the adult. A review of its incidence in a variety of conditions. Clin Orthop Relat Res. 1972;86:43–62.
3.Mwale F, Wang H, Johnson AJ, Mont MA, Antoniou J. Abnormal vascular endothelial growth factor expression in mesenchymal stem cells from both osteonecrotic and osteoarthritic hips. Bull NYU Hosp Jt Dis. 2011;69 Suppl 1:S56–61.
4.Atik OS. Overuse and abuse of cortisone. Eklem Hastalik Cerrahisi. 2017;28(1):1.
5.Mont MA, Zywiel MG, Marker DR, McGrath MS, Delanois RE. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am. 2010;92(12):2165–2170.
6.Yin JM LZ, Zhao SC, Guo YJ and Liu ZT. Relationship between the Apolipoprotein AI, B gene polymorphism and the risk of non-traumatic osteonecrosis. Lipids in health and disease. 2014;13:149.
7.Jones KB, Seshadri T, Krantz R, Keating A, Ferguson PC. Cell-based therapies for osteonecrosis of the femoral head. Biol Blood Marrow Transplant. 2008;14(10):1081–1087.
8.Kianmehr N, Bidari A, Mofidi M, Bahar N. Silent osteonecrosis of the femoral head following high-dose corticosteroids in patients with systemic rheumatic diseases. Med J Islam Repub Iran. 2015;29:259.
9.Jin H, Xu T, Chen Q, Wu C, Wang P, Mao Q et al. The Fate and Distribution of Autologous Bone Marrow Mesenchymal Stem Cells with Intra-Arterial Infusion in Osteonecrosis of the Femoral Head in Dogs. Stem Cells Int. 2016;2016:8616143.
10.Mont MA, Cherian JJ, Sierra RJ, Jones LC, Lieberman JR. Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today? A Ten-Year Update. J Bone Joint Surg Am. 2015;97(19):1604–1627.
11.Mont MA, Carbone JJ, Fairbank AC. Core decompression versus nonoperative management for osteonecrosis of the hip. Clin Orthop Relat Res. 1996;(324):169–178.
12.Koo KH, Kim R, Ko GH, Song HR, Jeong ST, Cho SH. Preventing collapse in early osteonecrosis of the femoral head. A randomised clinical trial of core decompression. J Bone Joint Surg Br. 1995;77(6):870–874.
13.Stulberg BN, Davis AW, Bauer TW, Levine M, Easley K. Osteonecrosis of the femoral head. A prospective randomized treatment protocol. Clin Orthop Relat Res. 1991;(268):140–151.
14.Tabatabaee RM, Saberi S, Parvizi J, Mortazavi SM, Farzan M. Combining Concentrated Autologous Bone Marrow Stem Cells Injection With Core Decompression Improves Outcome for Patients with Early-Stage Osteonecrosis of the Femoral Head: A Comparative Study. J Arthroplasty. 2015;30(9 Suppl):11–15.
15.Calori GM, Mazza E, Colombo M, Mazzola S, Mineo GV, Giannoudis PV. Treatment of AVN using the induction chamber technique and a biological-based approach: indications and clinical results. Injury. 2014;45(2):369–373.
16.Rackwitz L, Eden L, Reppenhagen S, Reichert JC, Jakob F, Walles H et al. Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head. Stem Cell Res Ther. 2012;3(1):7.
17.Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004;114(6):1502–1508.
18.Kuroda Y, Asada R, So K, Yonezawa A, Nankaku M, Mukai K et al. A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head. Int Orthop. 2016;40(8):1747–1754.
19.Hall MP, Band PA, Meislin RJ, Jazrawi LM, Cardone DA. Platelet-rich plasma: current concepts and application in sports medicine. J Am Acad Orthop Surg. 2009;17(10):602–608.
20.van der Jagt D, Mokete L, Pietrzak J, Zalavras CG, Lieberman JR. Osteonecrosis of the femoral head: evaluation and treatment. J Am Acad Orthop Surg. 2015;23(2):69–70.
21.Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein–4. J Clin Invest. 2002;110(6):751–759.
22.Carano RA, Filvaroff EH. Angiogenesis and bone repair. Drug Discov Today. 2003;8(21):980–989.
23.Yokota K, Ishida O, Sunagawa T, Suzuki O, Nakamae A, Ochi M. Platelet-rich plasma accelerated surgical angio-genesis in vascular-implanted necrotic bone: an experimental study in rabbits. Acta Orthop. 2008;79(1):106–110.
24.Yang C, Yang S, Du J, Li J, Xu W, Xiong Y. Vascular endothelial growth factor gene transfection to enhance the repair of avascular necrosis of the femoral head of rabbit. Chin Med J (Engl). 2003;116(10):1544–1548.
25.Chen J, Liu W, Cao Y, Zhang X, Guo Y, Zhu Y et al. MMP–3 and MMP–8 single-nucleotide polymorphisms are related to alcohol-induced osteonecrosis of the femoral head in Chinese males. Oncotarget. 2017;8(15):25177–25188.
26.Radke S, Battmann A, Jatzke S, Eulert J, Jakob F, Schutze N. Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head. J Orthop Res. 2006;24(5):945–952.
27.Nakamae A, Sunagawa T, Ishida O, Suzuki O, Yasunaga Y, Hachisuka H et al. Acceleration of surgical angiogenesis in necrotic bone with a single injection of fibroblast growth factor–2 (FGF–2). J Orthop Res. 2004;22(3):509–513.
28.Suzuki O, Bishop AT, Sunagawa T, Katsube K, Friedrich PF. VEGF-promoted surgical angiogenesis in necrotic bone. Microsurgery. 2004;24(1):85–91.
29.Broderick E, Infanger, S., Turner, T. M., and Sumner, D. R. . Inhibition of bone mineralization following high dose TGFβ 1 application. Presented at the 49th Annual Meeting of the Orthopedic Research Society, New Orleans, La. 2003.
30.Harten RD, Svach, D. J. Vascular endothelial growth factor inhibits DBM induced bone formation. Presented at the 49th Annual Meeting of the Orthopedic Research Society, New Orleans, La. 2003.
31.Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res. 2004;63(2):226–235.
32.Tong S, Yin J, Liu J. Platelet-rich plasma has beneficial effects in mice with osteonecrosis of the femoral head by promoting angiogenesis. Exp Ther Med. 2018;15(2):1781–1788.
33.Kamiya N, Yamaguchi R, Adapala NS, Chen E, Neal D, Jack O et al. Legg-Calve-Perthes disease produces chronic hip synovitis and elevation of interleukin–6 in the synovial fluid. J Bone Miner Res. 2015;30(6):1009–1013.
34.Yamaguchi R, Kamiya N, Adapala NS, Drissi H, Kim HK. HIF–1-Dependent IL–6 Activation in Articular Chondrocytes Initiating Synovitis in Femoral Head Ischemic Osteonecrosis. J Bone Joint Surg Am. 2016;98(13):1122–1131.
35.Rabquer BJ, Tan GJ, Shaheen PJ, Haines GK, 3rd, Urquhart AG, Koch AE. Synovial inflammation in patients with osteonecrosis of the femoral head. Clin Transl Sci. 2009;2(4):273–278.
36.Zou D, Zhang K, Yang Y, Ren Y, Zhang L, Xiao X et al. Th17 and IL–17 exhibit higher levels in osteonecrosis of the femoral head and have a positive correlation with severity of pain. Endokrynol Pol. 2018;69(3):283–290.
37.Adapala NS, Yamaguchi R, Phipps M, Aruwajoye O, Kim HKW. Necrotic Bone Stimulates Proinflammatory Responses in Macrophages through the Activation of Toll-Like Receptor 4. Am J Pathol. 2016;186(11):2987–2999.
38.Chiu WC, Lai YP, Chou MY. Humanization and characterization of an anti-human TNF-alpha murine monoclonal antibody. PLoS One. 2011;6(1):e16373.
39.Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318–328.
40.Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M et al. IL–6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. J Bone Miner Metab. 2014;32(4):378–392.
41.Bai F, Tian H, Niu Z, Liu M, Ren G, Yu Y et al. Chimeric anti-IL–17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis. Int J Mol Med. 2014;33(3):711–721.
42.Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui N et al. The role of p38 mitogen-activated protein kinase in IL–6 and IL–8 production from the TNF-alpha- or IL–1beta-stimulated rheumatoid synovial fibroblasts. FEBS Lett. 2000;465(1):23–27.
43.Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104(4):439–446.
44.Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J Biol Chem. 2007;282(33):24120–24130.
45.Tao SC, Yuan T, Rui BY, Zhu ZZ, Guo SC, Zhang CQ. Exosomes derived from human platelet-rich plasma prevent apoptosis induced by glucocorticoid-associated endoplasmic reticulum stress in rat osteonecrosis of the femoral head via the Akt/Bad/Bcl–2 signal pathway. Theranostics. 2017;7(3):733–750.
46.Mihailidou C, Panagiotou C, Kiaris H, Kassi E, Moutsatsou P. Crosstalk between C/EBP homologous protein (CHOP) and glucocorticoid receptor in lung cancer. Mol Cell Endocrinol. 2016;436:211–223.
47.Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem. 2001;276(14):10594–10601.
48.Houdek MT, Wyles CC, Collins MS, Howe BM, Terzic A, Behfar A et al. Stem Cells Combined With Platelet-rich Plasma Effectively Treat Corticosteroid-induced Osteonecrosis of the Hip: A Prospective Study. Clin Orthop Relat Res. 2018;476(2):388–397.
49.Ha YC, Jung WH, Kim JR, Seong NH, Kim SY, Koo KH. Prediction of collapse in femoral head osteonecrosis: a modified Kerboul method with use of magnetic resonance images. J Bone Joint Surg Am. 2006;88 Suppl 3:35–40.
50.Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med. 2004;8(3):301–316.
51.Pak J. Autologous adipose tissue-derived stem cells induce persistent bone-like tissue in osteonecrotic femoral heads. Pain Physician. 2012;15(1):75–85.
52.Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. J Med Case Rep. 2011;5:296.
53.Pak J, Lee JH, Jeon JH, Lee SH. Complete resolution of avascular necrosis of the human femoral head treated with adipose tissue-derived stem cells and platelet-rich plasma. J Int Med Res. 2014;42(6):1353–1362.
54.Giannoudis P, Tzioupis C, Almalki T, Buckley R. Fracture healing in osteoporotic fractures: is it really different? A basic science perspective. Injury. 2007;38 Suppl 1:S90–99.
55.Guadilla J, Fiz N, Andia I, Sanchez M. Arthroscopic management and platelet-rich plasma therapy for avascular necrosis of the hip. Knee Surg Sports Traumatol Arthrosc. 2012;20(2):393–398.
56.Samy AM. Management of osteonecrosis of the femoral head: A novel technique. Indian J Orthop. 2016;50(4):359–365.
57.Mont MA, Einhorn TA, Sponseller PD, Hungerford DS. The trapdoor procedure using autogenous cortical and cancellous bone grafts for osteonecrosis of the femoral head. J Bone Joint Surg Br. 1998;80(1):56–62.
58.D’Ambrosi R, Biancardi E, Massari G, Ragone V, Facchini RM. Survival Analysis after Core Decompression in Association with Platelet-Rich Plasma, Mesenchymal Stem Cells, and Synthetic Bone Graft in Patients with Osteonecrosis of the Femoral Head. Joints. 2018;6(1):16–22.
59.Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002;(405):14–23.
60.Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br. 1995;77(1):34–41.
61.Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study. Bone. 2011;49(5):1005–1009.
62.Gangji V, Hauzeur JP, Matos C, De Maertelaer V, Toungouz M, Lambermont M. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am. 2004;86-A(6):1153–1160.
63.Rosenwasser MP, Garino JP, Kiernan HA, Michelsen CB. Long term followup of thorough debridement and cancellous bone grafting of the femoral head for avascular necrosis. Clin Orthop Relat Res. 1994;(306):17–27.
64.Wang BL, Sun W, Shi ZC, Zhang NF, Yue DB, Guo WS et al. Treatment of nontraumatic osteonecrosis of the femoral head using bone impaction grafting through a femoral neck window. Int Orthop. 2010;34(5):635–639.
65.Yu PA, Peng KT, Huang TW, Hsu RW, Hsu WH, Lee MS. Injectable synthetic bone graft substitute combined with core decompression in the treatment of advanced osteonecrosis of the femoral head: A 5-year follow-up. Biomed J. 2015;38(3):257–261.
66.Amanatullah DF, Strauss EJ, Di Cesare PE. Current management options for osteonecrosis of the femoral head: part 1, diagnosis and nonoperative management. Am J Orthop (Belle Mead NJ). 2011;40(9):E186–192.
67.Zalavras CG, Lieberman JR. Osteonecrosis of the femoral head: evaluation and treatment. J Am Acad Orthop Surg. 2014;22(7):455–464.
68.Castro FP, Jr., Barrack RL. Core decompression and conservative treatment for avascular necrosis of the femoral head: a meta-analysis. Am J Orthop (Belle Mead NJ). 2000;29(3):187–194.
69.Rajagopal M, Balch Samora J, Ellis TJ. Efficacy of core decompression as treatment for osteonecrosis of the hip: a systematic review. Hip Int. 2012;22(5):489–493.
70.Yoon TR, Song EK, Rowe SM, Park CH. Failure after core decompression in osteonecrosis of the femoral head. Int Orthop. 2001;24(6):316–318.
71.Ahmad Z, Howard D, Brooks RA, Wardale J, Henson FM, Getgood A et al. The role of platelet rich plasma in musculoskeletal science. JRSM Short Rep. 2012;3(6):40.
72.Kitoh H, Kitakoji T, Tsuchiya H, Katoh M, Ishiguro N. Transplantation of culture expanded bone marrow cells and platelet rich plasma in distraction osteogenesis of the long bones. Bone. 2007;40(2):522–528.
73.Dallari D, Fini M, Stagni C, Torricelli P, Nicoli Aldini N, Giavaresi G et al. In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet-rich plasma, and freeze-dried bone allografts, alone and in combination. J Orthop Res. 2006;24(5):877–888.
74.Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2001;24(3):483–488.